Oslo - Delayed Quote NOK
Lytix Biopharma AS (LYTIX.OL)
7.60
-0.10
(-1.30%)
At close: May 16 at 4:25:26 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Operating Cash Flow
-70,372
-70,372
-95,969
-52,626
-44,607
Investing Cash Flow
24,693
24,693
29,725
-49,355
138
Financing Cash Flow
149,105
149,105
-943
-749
213,302
End Cash Position
130,791
130,791
27,365
94,552
197,282
Capital Expenditure
--
--
-49
-154
--
Issuance of Capital Stock
161,295
161,295
0
133
225,214
Repayment of Debt
--
--
-940
-827
-423
Free Cash Flow
-70,372
-70,372
-96,018
-52,780
-44,607
12/31/2021 - 6/14/2021
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CRNA.OL Circio Holding ASA
0.6270
-4.27%
PCIB.OL PCI Biotech Holding ASA
1.7600
-5.38%
BGBIO.OL BerGenBio ASA
1.7500
+2.58%
ZLNA.OL Zelluna ASA
13.75
-1.06%
ONCIN.OL Oncoinvent ASA
1.6060
+1.01%
FLUI.ST Fluicell AB (publ)
10.40
+1.96%
ABS.OL Arctic Bioscience AS
3.8500
+4.05%
BVNKF Bavarian Nordic A/S
26.80
0.00%
VRCA Verrica Pharmaceuticals Inc.
0.6623
+3.19%
BVNRY Bavarian Nordic A/S
8.24
+1.35%